Myeloablative chemotherapy and stem cell transplantation in myeloma or primary amyloidosis with renal involvement.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 16164623.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
High-dose chemotherapy and stem cell transplantation are being applied increasingly to the treatment of selected patients with multiple myeloma or primary systemic amyloidosis. Stem cell transplantation presents unique challenges to the nephrologist because of the high prevalence of renal involvement in myeloma and the issues that are associated with high-dose chemotherapy in patients with the nephrotic syndrome due to renal amyloid. We review the published literature on stem cell transplantation in patients with reduced renal function. The specifics of transplantation pertaining to patients with renal amyloid nephrotic syndrome are discussed in detail.
Medical subject headings
- Amyloidosis
- Hematopoietic Stem Cell Transplantation
- Multiple Myeloma
- Myeloablative Agonists
- Nephrotic Syndrome